In this touchINFECTIOUS DISEASES interview, we met with Dr Ruth Link-Gelles (Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA) to discuss the incidence of COVID-19 in children, vaccine effectiveness against infection and disease severity, and the current status of paediatric COVID-19 vaccines in the United States.
Interviews available in this series:
- What is known about the efficacy of COVID-19 in paediatric populations in terms of infection and disease severity? (0:17)
- What is the current status of paediatric COVID-19 vaccines in the United States? (1:04)
Disclosures: Ruth Link-Gelles has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Vaccines
The first mass reactive vaccination campaign against hepatitis E in Bentiu, South Sudan: Iza Ciglenecki, EASL 2023
Since 2015, cases of hepatitis E have been reported in the Bentiu camp in South Sudan, Africa, which hosts over 100,000 people displaced from conflict and flooding. The first mass reactive vaccination campaign against hepatitis E using the Hecolin® vaccine, the key findings of the campaign and unanswered questions, are discussed by Dr Iza Ciglenecki […]
The Hecolin® vaccine in the prevention of hepatitis E: Iza Ciglenecki, EASL 2023
A three-dose recombinant vaccine (Hecolin®) against hepatitis E has been licensed in China since 2011. We caught up with Dr Iza Ciglenecki (Médecins Sans Frontières, Geneva, Switzerland) to discuss the prognosis and treatment paradigm for hepatitis E, the challenges associated with optimizing hepatitis E vaccine efficacy and reducing the burden of disease, and what is […]
PHH-1V vaccine compared to BNT162b2 as a SARS-CoV-2 booster vaccine, phase IIb results: Patricia Muñoz García, ECCMID 2023
PHH-1V, a SARS-CoV-2 protein-based heterodimer vaccine was investigated in a phase IIb trial where the immunogenicity and safety of a heterologous booster with PHH-1V was assessed versus a homologous booster with BNT162b2 at 14, 28 and 98 days after vaccine administration. We spoke with Prof. Patricia Muñoz García (Gregorio Marañón General University Hospital, Madrid, Spain) […]